Overview
Mast cell disorders encompass a range of conditions characterized by abnormal mast cell proliferation or function, leading to diverse clinical manifestations including allergic reactions, inflammation, and autoimmune phenomena 2.Diagnosis
Identification of mast cell mediators (e.g., histamine) in affected tissues or bodily fluids.
Histopathological examination showing increased mast cell numbers or atypical morphology.
Functional assays demonstrating abnormal mast cell activation responses 3.Management
First-line treatments: Antihistamines for symptomatic relief of allergic manifestations.
Adjunctive therapies: Corticosteroids to reduce inflammation and mast cell activation.
Targeted therapies: Specific inhibitors of mast cell mediators or signaling pathways (dose-specific details not provided in abstracts).
Immunomodulatory agents: For managing autoimmune aspects, though specific recommendations vary 25.Special Populations
Pregnancy: Limited data; cautious use of systemic treatments, focusing on symptomatic management 3.
Pediatrics: Tailored approaches considering developmental differences; specific guidelines not detailed in abstracts.
Elderly: Increased vigilance for comorbidities; individualized treatment plans recommended 3.
Comorbidities: Integration of treatments for coexisting conditions, particularly those involving inflammation or immune dysregulation 3.Key Recommendations
Utilize histopathological examination for definitive diagnosis of mast cell disorders (Evidence: Moderate 3).
Employ antihistamines and corticosteroids as foundational treatments for symptom management (Evidence: Expert opinion 3).
Consider functional assays to assess mast cell activation status in complex cases (Evidence: Moderate 3).References
1 Crivellato E, Ribatti D. The fundamental contribution of William Bate Hardy to shape the concept of mast cell heterogeneity. British journal of haematology 2010. link
2 Beaven MA. Our perception of the mast cell from Paul Ehrlich to now. European journal of immunology 2009. link
3 Maurer M, Metz M. The status quo and quo vadis of mast cells. Experimental dermatology 2005. link
4 Alles JU, Bosslet K. Immunohistochemical and immunochemical characterization of a new endothelial cell-specific antigen. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 1986. link
5 Litchfield DW, Ball EH. Phosphorylation of the cytoskeletal protein talin by protein kinase C. Biochemical and biophysical research communications 1986. link90388-8)
6 Nielsen EH, Johansen T. Effects of dimethylsulfoxide (DMSO), nocodazole, and taxol on mast cell histamine secretion. Acta pharmacologica et toxicologica 1986. link